Research Topics
Genomes and GenesSpecies | Jan Jacques MichielsSummaryAffiliation: University Hospital Antwerp Country: Belgium Publications
| Collaborators
|
Detail Information
Publications
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3Jan Jacques Michiels
Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
Clin Appl Thromb Hemost 13:14-34. 2007....- Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophJan Jacques Michiels
Department of Hematology, University Hospital Antwerp, Hemostasis Thrombosis Research, Antwerp, Belgium
Platelets 17:528-44. 2006.... - Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand diseaseJan Jacques Michiels
Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
Clin Appl Thromb Hemost 12:397-420. 2006..2E appears to be less well defined, is usually autosomal dominant, and accounts for about one third of patients with 2A in a large cohort of VWD patients... - Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWDJan Jacques Michiels
Department of Hematology, Hemostasis and Thrombosis Research, University Hospital Antwerp
Clin Appl Thromb Hemost 12:277-95. 2006..A DDAVP challenge test clearly differentiates between dominant type 1 VWD phenotype and dominant type 2 M VWD... - Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiencesJan Jacques Michiels
Department of Hematology, University Hospital Antwerp, Belgium
Semin Thromb Hemost 31:577-601. 2005..Proper recommendations of FVIII/vWF concentrates using FVIII:C and vWF:RCo unit dosing for the prophylaxis and treatment of bleeding episodes in type 2 disease that is nonresponsive to DDAVP and in type 3 vWD are proposed... - Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadinJan Jacques Michiels
Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
Blood Cells Mol Dis 36:199-205. 2006..000/microl)... 
Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von WilAlain Gadisseur
Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
Acta Haematol 121:128-38. 2009....- Laboratory diagnosis and molecular classification of von Willebrand diseaseAlain Gadisseur
Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
Acta Haematol 121:71-84. 2009..2 to 4.69 indicating clearance of the VWF/FVIII complex. Normal VWFpp/Ag ratios in mild VWD type 1 with mutations in the D1-D2 and the D4-B-C domains reflect a synthesis/secretion defect... - Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor geneAlain Gadisseur
Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
Acta Haematol 121:145-53. 2009..The laboratory manifestations and molecular defects in the A1 domain causing VWD type 2M and 2U are clearly distinct from all variants of type 1 VWD and also from all other variants [VWD type 2A, 2B, 2E (IIE) and 2C (IIC)]... - Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P)Jan Jacques Michiels
Haemostasis and Thrombosis Research, Department of Haematology, Antwerp University Hospital, University of Antwerp, Belgium
Blood Coagul Fibrinolysis 15:323-30. 2004.... - Screening for deep vein thrombosis and pulmonary embolism in outpatients with suspected DVT or PE by the sequential use of clinical score: a sensitive quantitative D-dimer test and noninvasive diagnostic toolsJan Jacques Michiels
Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
Semin Vasc Med 5:351-64. 2005..The combination of clinical assessment, a rapid ELISA VIDAS D-dimer, followed by CUS will reduce the need for helical spiral CT by 40 to 50%... - WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disordersJan Jacques Michiels
Department of Hematology, University Hospital, Antwerp, Belgium
Leuk Res 31:1031-8. 2007..The proposed WHO/ECMP criteria allow a cross talk between clinicians, pathologists and scientists to much better characterize the nature and natural history of each of the WHO/CMP defined early and overt MPDs... - Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemiaJan Jacques Michiels
Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
Ann Hematol 83:504-12. 2004..These observations indicate that both Ph+ ET and Ph+ thrombocythemia associated with CML can be regarded as early manifestations of the chronic stable phase of CML... - Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia)Jan Jacques Michiels
Department of Hematology, University Hospital Antwerp, University of Antwerp, Belgium
Int J Hematol 76:133-45. 2002..On the other hand, survival is substantially shortened in IMF/AMM, even for patients with thrombocythemia as a frequent finding of prefibrotic and early stage IMF/AMM... - Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia veraJan Jacques Michiels
Department of Haematology, Haemostasis Thrombosis Research, University Hospital Antwerp, Antwerp, Belgium
Platelets 15:67-84. 2004..The microvascular syndrome associated with thrombocythaemia in PV patients in remission after bloodletting is best controlled by low-dose aspirin (50-100 mg/day) or by reduction of platelet count to normal (< 350 x 10(9)/l)... - Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyondJan Jacques Michiels
Department of Hematology, University Hospital Antwerp, Belgium
Hematology 10:215-23. 2005.... - Ximelagatran as a new oral anticoagulant for thrombosisOla E Dahl
Thrombosis Research Institute, London, United Kingdom
Semin Vasc Med 5:223-5. 2005 - The use of aspirin and clinical implications in essential thrombocythemiaJan Jacques Michiels
Semin Thromb Hemost 32:646-8. 2006 - Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasiaJan Jacques Michiels
Goodheart Institute, MPD Center Europe, Rotterdam, The Netherlands
Hematol J 5:93-102. 2004.... - Preface: platelets in inflammation and atherothrombosisJan Jacques Michiels
Bloodcoagulation Research in Vascular Medicine, University Hospital Antwerp, Faculty of Medicine, Antwerp University, Goodheart Institute, Hemostasis Thrombosis Research and Science Center, Erasmus Tower, Rotterdam, The Netherlands
Semin Thromb Hemost 33:119-22. 2007 - Low protein Z associated with venous thrombophilia and with ischemic strokeJan Jacques Michiels
Semin Vasc Med 2:121-4. 2002